Global leader in data-driven medicine SOPHiA GENETICS has closed a $110 million financing round to enter the next stage of its expansion, with a focus on supporting the growing clinical and biopharma demand for data-driven medicine worldwide.
Having established the world’s largest data-driven medicine community network through its universal and collaborative AI platform, SOPHiA GENETICS supports healthcare professionals by translating multiple sources of complex medical data into valuable clinical insights. The SOPHiA Platform is used by over 1,000 healthcare institutions and has analyzed 600,000 genomic profiles (up to 17,000 new profiles a month).
Led by aMoon, a leading health-tech & life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group, the new funding round in the amount of $110 million will boost the company’s penetration in both the US and Asian markets.
Moreover, this Series F round will also be dedicated to increasing the platform multimodal capabilities and its adoption by healthcare institutions worldwide, allowing SOPHiA GENETICS to optimize and accelerate the development of new targeted therapies.
“SOPHiA has established an impressive track record of disrupting healthcare and enabling a decentralized approach. This new funding round will further strengthen SOPHiA’s already unique offering, performance, and life-changing impact on patients and targeted therapies,” said Troy Cox, Chairman of the Board of Directors of SOPHiA GENETICS.
A success story from the Health Valley
Founded in 2011 on the EPFL Innovation Park, SOPHiA Genetics is now headquartered in Saint-Sulpice in the canton of Vaud and employs more than 300 people. “Since inception, we knew that leveraging a wide range of data modalities powered by cutting-edge technologies was key to sustainably deliver better outcomes to the global healthcare community,” concluded Jurgi Camblong, CEO and Founder at SOPHiA GENETICS. “Now, with this new funding round, we can embark on the next stage of our development and take our collaborative approach further, delivering intelligent medicine, together.”